AKT1 and neoplasm: In cluster 2 with deletions in RB1, BRCA2 and PTEN, for example, the oral pan-AKT Inhibitor MK-2206 has been shown to decrease tumour size and CA19–9 levels in PDAC patients with PTEN loss [24] and the PARP inhibitor olaparib prolonged progression-free survival in metastatic PDAC patients with BRCA1/2 mutations [25].